First United Kingdom Heart and Renal Protection (UK-HARP-I) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 45 (3), 473-484
- https://doi.org/10.1053/j.ajkd.2004.11.015
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditionsThe Lancet, 2004
- Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialThe Lancet, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Pravastatin Therapy and the Risk of StrokeThe New England Journal of Medicine, 2000
- Premature cardiovascular disease in chronic renal failureThe Lancet, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998
- Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular DiseaseAmerican Journal of Kidney Diseases, 1998
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsThe New England Journal of Medicine, 1996
- Death Risk in Hemodialysis Patients: The Predictive Value of Commonly Measured Variables and an Evaluation of Death Rate Differences Between FacilitiesAmerican Journal of Kidney Diseases, 1990
- Mortality Risk Factors in Patients Treated by Chronic HemodialysisNephron, 1982